【摘要】 为了研究骨髓增生异常综合征的治疗效果 ,应用雄激素康力龙或丹那唑联合小剂量全反式维甲酸 (A TRA)治疗 5 5例骨髓增生异常综合征 (MDS) ,其中RA 4 1例、RAEB 11例、RAEB t 2例、CMML 1例。给药方法 :丹那唑 60 0mg/d或康力龙 6mg/d ,ATRA 10mg/d ,疗程至少 3月。结果表明 :治疗 3个月后在 5 3例可评价者中 ,按照MDS国际工作组疗效标准判定 ,完全缓解 1例 ( 1.9% ) ,部分缓解 2例 ( 3 .8% ) ;在血液学改善方面显效 15例( 2 8.3 % ) ,微效 4例 ( 7.5 % ) ,总有效率 3 6.5 %。继续进行追访 ,中位时间 4月 ( 0 - 4 8个月 ) ,总有效率 3 9.6%。治疗前后骨髓原始细胞无显著变化 ,病态造血仅 3例明显改善。结论 :雄激素联合小剂量ATRA对低危险组MDS是一种比较有效、经济的治疗方法。更多还原

【Abstract】 To explore therapeutic efficacy of androgens and low dose all trans retinoic acid (ATRA) for myelodysplastic syndrom (MDS) patients, 55 patients of MDS were observed, including 41 cases of refractory anemia (RA), 11 cases of refractory anemia with excess of blasts (RAEB), 2 cases of refractory anemia with excess of blasts in transformation (RAEB t) and 1 case of chronic myeloic monocytic leukemia (CMML). These patients received danazol (600 mg/day) or stanazol (6 mg/day) and ATRA (10 mg/day) for at least 3 months. The results showed that according to MDS international working group response criteria, at the end of three months, complete remission (CR) was seen in 1 patient, partial remission (PR) was found in 2 patients. Hematologic improvement: major response (MaR) were seen in 15 patients, minor response (MiR) were seen in 4 patients. The total response rate was 35 8%. In conclusion, danazol or stanazol in combination with low dose ATRA are partialy effective in therapy for patients with low risk myelodysplastic syndrome.更多还原